» Articles » PMID: 9589673

The Insulin-like Growth Factor Axis and Growth in Children with Chronic Renal Failure: a Report of the Southwest Pediatric Nephrology Study Group

Overview
Specialty Endocrinology
Date 1998 May 20
PMID 9589673
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Children with chronic renal failure (CRF) are often growth recarded despite normal serum levels of GH and insulin-like growth factors (IGFs). Recent studies suggest that excess IGF-binding proteins (IGFBPs) in the 35-kDa fractions of CRF serum contribute to CRF growth failure. This report characterizes the relationship between IGFBP-3 and IGF peptides in the serum of growth-retarded CRF children. Size-exclusion chromatography at pH 7.4 found IGFBP-3 and IGFs almost exclusively in the 150-kDa fractions of normal serum, where their molar stoichiometry was approximately 1:1. However, similar chromatography of CRF serum found a molar excess of IGFBP-3 over total IGFs in the 150-kDa fractions and large amounts of IGFs in the 35-kDa fractions. In the 150-kDa fractions of CRF serum, IGFBP-3 was present in normal amounts, but a greater than normal amount was in the form of a 29-kDa IGFBP-3 fragment. Treatment of these CRF children with recombinant human GH increased the molar excess of IGFBP-3 over total IGFs in the 150-kDa fractions, the amount of IGFBP-3 and total IGFs in the 150-kDa fractions, and the amount of IGFs, but not IGFBPs, in the 35-kDa fractions. These data suggest that in untreated CRF children, proteolysis of IGFBP-3 in the 150-kDa fractions releases IGFs to the excess IGFBPs in the 35-kDa fractions, but insufficient IGF is released to overcome the growth-inhibiting effects of these excess IGFBPs. Treatment with recombinant human GH increases levels of IGFs and IGFBP-3 in the 150-kDa fractions, and subsequent IGFBP-3 proteolysis releases sufficient IGF to overcome the growth inhibitory effects of excess IGFBPs in the 35-kDa fractions of CRF serum.

Citing Articles

Growth Hormone and IGF1 Actions in Kidney Development and Function.

Gurevich E, Segev Y, Landau D Cells. 2021; 10(12).

PMID: 34943879 PMC: 8699155. DOI: 10.3390/cells10123371.


Renal effects of growth hormone in health and in kidney disease.

Haffner D, Grund A, Leifheit-Nestler M Pediatr Nephrol. 2021; 36(8):2511-2530.

PMID: 34143299 PMC: 8260426. DOI: 10.1007/s00467-021-05097-6.


Pubertal development in children with chronic kidney disease.

Haffner D, Zivicnjak M Pediatr Nephrol. 2016; 32(6):949-964.

PMID: 27464647 DOI: 10.1007/s00467-016-3432-3.


Insulin-like growth factor-1 bioactivity plays a prosurvival role in older participants.

Maggio M, Cattabiani C, Lauretani F, Bandinelli S, De Vita F, DallAglio E J Gerontol A Biol Sci Med Sci. 2013; 68(11):1342-50.

PMID: 23671288 PMC: 3805296. DOI: 10.1093/gerona/glt045.


Chronic kidney disease: mineral and bone disorder in children.

Wesseling-Perry K, Salusky I Semin Nephrol. 2013; 33(2):169-79.

PMID: 23465503 PMC: 4209124. DOI: 10.1016/j.semnephrol.2012.12.017.